Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Trial Profile

Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Cetuximab (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms JACCRO CC-08
  • Most Recent Events

    • 15 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Oct 2016 Primary endpoint (Progression-free survival rate) has been met.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top